Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis. - Wikidata - awgldk - TriplyDB

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

http://www.wikidata.org/entity/Q37762829

about

Novel adjunctive therapies for the treatment of tuberculosis Epidemiology and management of common pulmonary diseases in older persons Lymphoid tissue damage in HIV-1 infection depletes naïve T cells and limits T cell reconstitution after antiretroviral therapy.Exploratory analysis of a phase III trial of pirfenidone identifies a subpopulation of patients with idiopathic pulmonary fibrosis as benefiting from treatment Hepatocyte growth factor is an attractive target for the treatment of pulmonary fibrosis.Emerging therapeutic interventions for idiopathic pulmonary fibrosis.Pirfenidone as salvage treatment for refractory bleomycin-induced lung injury: a case report of seminoma.Anti-fibrotic nintedanib-a new opportunity for systemic sclerosis patients?The antifibrotic agent pirfenidone inhibits angiotensin II-induced cardiac hypertrophy in mice.Pirfenidone treatment of idiopathic pulmonary fibrosis

P2860

Q26829957-645B477C-2D67-4DAB-BFE6-871EBBA38F68 Q28397465-32CA0D55-3918-4330-B458-2769577A0C20 Q34126302-B21E2776-C70C-42DE-A8BC-CA773CFBF36A Q35551942-531CEAAE-9965-4358-AE1C-90E5AAB931D1 Q38088776-B479AE20-E961-4B8F-95E2-A9DD1C94EA8A Q38207153-D1BF1F6F-6485-4F0F-9502-F7F17C002FA1 Q40044336-6DCD4C0A-E72E-4F2E-A151-B5DC3C617064 Q47607468-2E4FFA86-766B-4055-8FD4-2B0F3BEC1186 Q48933675-801C25C0-6D09-4D22-B6C1-AE5A7E0F18AD Q56905292-9132B640-66C4-4070-9587-3CC81B077C65

P2860

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

http://www.wikidata.org/entity/Q37762829

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

@en

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

@nl

type

label

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

@en

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

@nl

prefLabel

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

@en

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

@nl

P1433

Q37762829-58F3F579-580E-4BC9-AC47-7371CE788952

P1476

Q37762829-1D2F268E-6659-4078-8D52-F73F9E1D5710

P2093

Q37762829-C4F3C17F-2C3E-4E59-AE74-37D43DF9BAAC

P2860

Q37762829-1C345FEE-0B56-4D52-86E8-3C2700148A14

Q37762829-2240FFEF-BCAE-4D03-8076-DBAD69839C02

Q37762829-2F41AEEE-39D1-4FA9-8545-0ECBAC0C0642

Q37762829-3205351F-C36B-404F-9F28-7B9C6B4C3CFB

Q37762829-361C0A01-D65E-4D1E-8459-D3F4BB26675B

Q37762829-3B7116B0-C228-4023-A2B2-04830F534BF1

Q37762829-3DE0E02C-BBD6-46EC-BC11-A441C51966BA

Q37762829-52FC4D34-A66F-434E-8B9B-3852734EF46C

Q37762829-60C9AAB5-327F-453C-B9C5-282F3F764D30

Q37762829-6F84F2E4-F911-422D-9607-D17FBBE069F6

P304

Q37762829-7B2AAF41-DC83-4DC5-94A8-E81A554215A2

P31

Q37762829-7C4A13C1-5B52-4A4D-BC17-6C998CACEF7F

P356

Q37762829-7FEB097F-A84C-4FCB-BB08-E17B6E7ED176

P433

Q37762829-F6BA5CD7-2CCC-4C49-867A-CB88132FA2C3

P478

Q37762829-5BD1A0E1-14F1-4AD0-BB9E-3695B74AFBE8

P577

Q37762829-1C16C0FC-06A8-4973-B341-11C3A957E5E4

P698

Q37762829-84259DD8-B607-4AF7-BDF5-E49F2921AA95

P921

Q37762829-8401FCB4-E68E-46E5-9BB5-5FAFAF4EA289

P356

P1433

Expert Review of Respiratory Medicine

P1476

Pirfenidone: antifibrotic agent for idiopathic pulmonary fibrosis.

@en

P2093

Arata Azuma

http://www.w3.org/2001/XMLSchema#string

P2860

Pirfenidone in idiopathic pulmonary fibrosis

High-dose acetylcysteine in idiopathic pulmonary fibrosis

Incidence and prevalence of idiopathic pulmonary fibrosis.

Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis.

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.

Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults.

Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.

Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis

Strategies for treating idiopathic pulmonary fibrosis.

P304

301-310

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERS.10.32

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2010-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20524912

http://www.w3.org/2001/XMLSchema#string

P921

pulmonary fibrosis